Thalidomide regains respectability as new benefits are discovered

Pharmaceutical Journal

Volumn 267, Issue 7158, 2001, Pages 124-127

  Allen, B Roger ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

THALIDOMIDE;

CONSTIPATION; DISCOID LUPUS ERYTHEMATOSUS; DRUG EFFICACY; DRUG INDICATION; DRUG MARKETING; DRUG MECHANISM; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; ENDOCRINE DISEASE; ERYTHEMA NODOSUM LEPROSUM; GENITAL ULCER; GRAFT VERSUS HOST REACTION; HUMAN; LIMB DEFECT; MOUTH ULCER; NAUSEA; NEUROPATHY; PRURIGO; RASH; RISK BENEFIT ANALYSIS; SEDATION; SHORT SURVEY; TERATOGENICITY; XEROSTOMIA;

EID: 0035963958     PISSN: 00316873     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (46)

1. Koch HP. Thalidomide and cogeners as anti-inflammatory agents. In: Ellis GP, West GB (editors) Progress in Medicinal Chemistry 1985;22:165-242.
2. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991;173:699-703.
3. Raza A. Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes. Microscopy Res Technique 2000;50:229-35.
4. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proceedings Nat Acad Sci 1994;91:4082-5.
5. Chen T-L, Vogelsang GB, Petty BG, Brundrett RB, Noe DA, Santos GW, et al Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. Drug Metab Disposition 1989;17:402-5.
6. Fullerton PM, O'Sullivan DJ. Thalidomide neuropathy: a clinical, electrophysiological and histological follow up study. J Neurol Neurosurg Psych 1968;31:543-51.
7. Gunzler V. Thalidomide in human immunodeficiency virus. A review of safety considerations. Drug Safety 1992;7:116-34.
8. Lagueny J, Rommel A, Vignolly B, Taieb A, Vendeaud-Busquet M, Doutre MS, et al. Thalidomide neuropathy: an electrophysiological study. Muscle Nerve 1986;9:837-44.
9. Mellin GW, Katzenstein M. The saga of thalidomide. New EnglJ Med 1962;267:1184-93 and 1238-44.
10. Somers GF. Pharmacological properties of thalidomide (aphthalimido glutarimide): new sedative hypnotic drug. Br J Pharmacol Chemother 1960;15:111-6.
11. Jung H. Klinische Erfahrungen mit einem neuen Sedativum. Arnzneimittelforschung 1956;6:430-2.
12. Kunstmann AH. Erfahrungen mit Contergan in der Kinderheilkunde. Therap Gegenw 1960;99:106-9.
13. Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 1965;6:303-6.
14. Thalidomide in leprosy reaction (leading article). Lancet 1994;343:432-3.
15. Sheskin J, Convit J. Controlled trial of thalidomide in ENL 58 patients. Hautarzt 1966;17:548-9.
16. Sheskin J. The treatment of lepra reaction in lepromatous leprosy: fifteen years experience with thalidomide. Int J Dermatol 1980;19:318-22.
17. Mascaro JM, Lecha M, Torras H. Thalidomide in the treatment of recurrent necrotic and giant mucocutaneous aphthae and aphthosis. Arch Dermatol 1979;115:636-7.
18. Saylan T, Saltik I. Thalidomide in the treatment of Behçet's syndrome. Arch Dermatol 1982;118:536.
19. Jenkins JS, Powell RJ, Allen BR, Littlewood SM, Maurice PD, Smith NJ. Thalidomide in severe orogenital ulceration. Lancet 1984;iv:1424-6.
20. Saurat J-H, Camenzind M, Helg C, Chapuis B. Thalidomide for graft-versus-host disease after bone marrow transplantation. Lancet 1988;i:359.
21. Lim SH, McWhannell A, Vora AJ, Boughton BJ. Successful treatment with thalidomide of acute graft-versus-host disease after bone marrow transplantation. Lancet 1988;i:117.
22. Rovelli A, Arrigo C, Nesi F, Balduzzi A, Nicolini B, Locasciulli A, et al. The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children. Bone Marrow Transplantation 1998;21:577-81.
23. Ringden O, Aschan J, Westerberg L. Thalidomide for severe graft versus host disease. Lancet 1988;iii:568.
24. Londoño F. Thalidomide in the treatment of actinic prurigo. Int J Dermatol 1973;12:326-8.
25. Rubio BJ, Gonzales FF. Lupus eritematoso discoide y talidomida. Informe preliminar dermatologia. Dermatol Rev Mex 1975;19:131-9.
26. Barnhill RL, McDougall AC. Thalidomide: use and possible mode of action in reactional lepromatous leprosy and various other conditions. J Am Acad Dermatol 1982;7:317-23.
27. Mattos O. Prurigo nodular de hyde tratado con talidomida. Bol Div Nac Lepra 1973;32:71-7.
28. Smith NJ, Jenkins JS, Powell RJ, Allen BR, Littlewood SM, Maurice PDL. Nerve conduction studies in patients taking thalidomide for orogenital ulceration. In: Lehner T, Barnes CG (editors). Recent advances in Behçet's disease. Royal Society of Medicine Services International Congress and Symposium Series No.103. London: Royal Society of Medicine Services; 1986. pp.369-72.
29. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. New Engl J Med 1999;341:1565-71.
30. Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, et al. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clinic Proceedings 2000;75:897-901.
31. Kneller A, Raanani P, Hardan I, Avigdor A, Levi I, Berkowicz M, et al. Therapy with thalidomide in refractory multiple myeloma patients -the revival of an old drug. Br J Haematol 2000;108:391-3.
32. Juliusson G, Celsing F, Turesson I, Lenhoff S, Adriansson M, Malm C. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol 2000;109:89-96.
33. Youle M, Clarbour J, Farthing C, Connolly M, Hawkins D, Staughton R, et al. Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody. BMJ 1989;289:432.
34. Ghigliotti GM, Repetto T. Thalidomide: treatment of choice for aphthous ulcers in patients seropositive for human immunodeficiency virus. J Am Acad Dermatol 1993;28:271-2.
35. Gorin I, Vilette B, Gehanno P, Escande JP. Thalidomide in hyperalgic pharyngeal ulceration in AIDS. Lancet 1990;335:1343.
36. Jacobson JM, Greenspan JS, Spritzler J, Ketter N, Fahey JL, Jackson JB, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. New Engl J Med 1997;336:1487-93.
37. Jacobson JM, Spritzler J, Fox L, FaheyJL, Jackson JB, Chernoff M, et al. Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. J Infect Dis 1999;180:61-7.
38. Little RF, Wyvill KM, Pluda JM, Welles L, Marshall V, Figg WD, et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 2000;18:2593-602.
39. Fife K, Howard MR, Gracie F, Phillips RH, Bower M. Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre. Int J STD AIDS 1998;9:751-5.
40. Reyes-Teran G, Siera-Madero JG, Martinez del Cerro V, Arroyo-Figueroa, Pasquetti A, Calva JJ, et al. Effects of thalidomide on HIV-associated wasting syndrome; a randomised double-blind placebo controlled clinical trial. AIDS 1996; 10:1501-7.
41. Sharpstone D, Rowbottom AW, Nelson NM, Gazzard B. The treatment of microsporidial diarrhea with thalidomide AIDS 1995;9:658-9.
42. Sulva SRB, Viana PCF, Lugon NV, Hoette M, Ruzany F, Lugon JR. Thalidomide for the treatment of uraemic pruritus: a crossover randomised double-blind trial. Nephron 1994;67: 270-3.
43. Vasiliauskas EA, Kam LY, Abreu-Martin MT, Hassard PV, Papadakis KA, Yang H, et al. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology 1999;117:1278-87.
44. Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer SB. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 1999;117:1271-7.
45. Muller-Quernheim J. Sarcoidosis: immunopathogeneic concepts and their clinical application. Eur Resp J 1998;12:716-38.
46. Corral LG, Kaplan G. Immunomodulation by thalidomide and thalidomide analogues. Ann Rheum Dis 1999;58(Suppl1):I107-113.